Five Key Takeaways From Merck’s Q2 Earnings Release

01 Aug 2023

Keytruda and Gardasil lead Merck’s growth story, although Lagevrio’s ongoing decline placed a drag on quarterly performance. Lung cancer is driving Keytruda’s momentum outside the US.

Merck & Co., Inc. reported a strong financial performance on 1 August for the second quarter, led by continued high growth for Keytruda and Gardasil, while warning that sales trends for those two products might fall off somewhat during the second half of the year. But the company’s district court challenge to portions of last year’s Inflation Reduction Act (IRA) took center stage during the same-day earnings call.

Here are five key takeaways from the New Jersey pharma’s second quarter: